Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Down 72.2% in May

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,897 shares, a drop of 72.2% from the April 30th total of 10,427 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,614 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bone Biologics has an average rating of “Sell”.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC grew its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Bone Biologics Stock Performance

Shares of BBLG traded up $0.02 during midday trading on Friday, hitting $1.32. The stock had a trading volume of 41,705 shares, compared to its average volume of 12,725. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $6.75. The business has a 50-day simple moving average of $1.26 and a two-hundred day simple moving average of $1.44.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). On average, equities research analysts expect that Bone Biologics will post -1.52 earnings per share for the current year.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.